DM
Therapeutic Areas
Thermo Fisher Scientific Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TAK-280 | Metastatic Castration-Resistant Prostate Cancer | Phase 2 |
| TAK-500 | Advanced Solid Tumors | Phase 1/2 |
| TAK-676 | Advanced/Metastatic Solid Tumors | Phase 1/2 |
| TAK-186 | Undisclosed Oncology | Phase 1 |
| TAK-954 | Postoperative Ileus | Phase 2 |
| TAK-671 | Acute Pancreatitis | Phase 2 |
| TAK-648 | Diabetic Macular Edema | Phase 2 |
| TAK-041 | Anhedonia in Depression & Schizophrenia | Phase 2 |
Leadership Team at Thermo Fisher Scientific
MN
Marc N. Casper
President and Chief Executive Officer
SW
Stephen Williamson
Senior Vice President and Chief Financial Officer
DK
Dr. Karen Nelson
Senior Vice President and Chief Scientific Officer
JP
Jim P. Manzi
Chairman of the Board